RNAi manipulations of DC to enhance HIV immunogenicity

DC 的 RNAi 操作增强 HIV 免疫原性

基本信息

项目摘要

DESCRIPTION (provided by applicant): To date there is no effective vaccine for HIV infection. Although a major vaccine trial based on homologous recombinant viral prime/boost failed recently, a study undertaken later, in a monkey model, suggests that with a more appropriate heterologous prime/boost regimen, it is possible to elicit a strong T cell response that protects against virulent viral challenge. Thus, for a vaccine to be effective, it should be able to evoke a strong and broad-based T cell response. Moreover, pretesting the relevance of novel vaccine approaches by HIV challenge in preclinical models would greatly help prevent the agony of vaccine failures in human clinical trials. As Dendritic cells are critical for induction of T cell immune responses, we hypothesize that immunization with HIV proteins targeted to dendritic cells in which select negative immunomodulatory molecules such as SOCS-1, PD-L1, L2 and IL-10 have been suppressed by RNA interference will elicit a potent polyfunctional CD8+ T cell response. Our hypothesis is based on our preliminary results in which silencing of SOCS-1 via targeted siRNA delivery to DC was enough to elicit a robust primary T cell response in vitro to several HIV gag epitopes, including subdominant ones. Moreover, we have recently shown the feasibility of using the latest versions of humanized mouse models to test the efficacy of siRNA mediated interventions in HIV infection and are thus are in a position to test whether the human DC- targeted methods are effective in vivo. In Specific Aim 1 of this proposal we will develop methods and reagents for targeted delivery of HIV-antigens and immunomodulatory siRNA reagents to human DCs. These will include a DC targeting peptide modified to bind siRNA as well as to deliver HIV antigens, two DC-targeting antibody fused to HIV proteins and further modified to bind siRNAs and a liposomal formulation that allows targeted delivery of siRNA and HIV antigen in mRNA form. In Aim 2, we will evaluate whether co-delivery of HIV immunogen with the different immunomodulatory siRNA (singly and in combination) by any of these methods is able to induce a broad and polyfunctional primary HIV-specific CD8 T cell response in vitro. In Aim 3, we will validate the in vitro findings as well as test the efficacy of our methods to actually confer protection from in vivo HIV challenge in the humanized BLT mouse model transgenic for HLA-A2 and HLA-B27.
描述(由申请人提供):迄今为止,没有有效的艾滋病毒感染疫苗。尽管最近基于同源重组病毒初免/加强的主要疫苗试验失败,但后来在猴模型中进行的一项研究表明,采用更合适的异源初免/加强方案,有可能引发强烈的T细胞应答,保护免受强毒病毒攻击。因此,要使疫苗有效,它应该能够引起强烈和广泛的T细胞反应。此外,通过在临床前模型中进行HIV攻击来预先测试新疫苗方法的相关性,将大大有助于防止疫苗在人体临床试验中失败的痛苦。由于树突状细胞对于诱导T细胞免疫应答是至关重要的,我们假设用靶向树突状细胞的HIV蛋白免疫,其中选择的负性免疫调节分子如SOCS-1、PD-L1、L2和IL-10已被RNA干扰抑制,这将引发有效的多功能CD 8 + T细胞应答。我们的假设是基于我们的初步结果,其中通过靶向siRNA递送至DC的SOCS-1沉默足以在体外引发对几种HIV gag表位(包括亚显性表位)的强大的初级T细胞应答。此外,我们最近已经显示了使用最新版本的人源化小鼠模型来测试siRNA介导的干预在HIV感染中的功效的可行性,因此能够测试人DC靶向方法是否在体内有效。在本提案的具体目标1中,我们将开发用于将HIV抗原和免疫调节siRNA试剂靶向递送至人DC的方法和试剂。这些将包括经修饰以结合siRNA以及递送HIV抗原的DC靶向肽、与HIV蛋白融合并经进一步修饰以结合siRNA的两种DC靶向抗体以及允许以mRNA形式靶向递送siRNA和HIV抗原的脂质体制剂。在目的2中,我们将评估通过这些方法中的任一种共递送HIV免疫原与不同的免疫调节siRNA(单独和组合)是否能够在体外诱导广泛和多功能的初级HIV特异性CD 8 T细胞应答。在目标3中,我们将验证体外发现以及测试我们的方法在HLA-A2和HLA-B27转基因的人源化BLT小鼠模型中实际赋予体内HIV攻击保护的功效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Premlata Shankar其他文献

Premlata Shankar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Premlata Shankar', 18)}}的其他基金

Role of PD-1H mediated monocyte activation in HIV pathogenesis
PD-1H 介导的单核细胞激活在 HIV 发病机制中的作用
  • 批准号:
    8789272
  • 财政年份:
    2014
  • 资助金额:
    $ 36.64万
  • 项目类别:
Role of PD-1H mediated monocyte activation in HIV pathogenesis
PD-1H 介导的单核细胞激活在 HIV 发病机制中的作用
  • 批准号:
    8906933
  • 财政年份:
    2014
  • 资助金额:
    $ 36.64万
  • 项目类别:
HIV protection by ZFN-based disruption of CCR5 gene in Hematopoietic stem cells
基于 ZFN 的造血干细胞 CCR5 基因破坏对 HIV 的保护
  • 批准号:
    8517184
  • 财政年份:
    2012
  • 资助金额:
    $ 36.64万
  • 项目类别:
HIV protection by ZFN-based disruption of CCR5 gene in Hematopoietic stem cells
基于 ZFN 的造血干细胞 CCR5 基因破坏对 HIV 的保护
  • 批准号:
    8413587
  • 财政年份:
    2012
  • 资助金额:
    $ 36.64万
  • 项目类别:
RNAi manipulations of DC to enhance HIV immunogenicity
DC 的 RNAi 操作增强 HIV 免疫原性
  • 批准号:
    8523759
  • 财政年份:
    2009
  • 资助金额:
    $ 36.64万
  • 项目类别:
RNAi manipulations of DC to enhance HIV immunogenicity
DC 的 RNAi 操作增强 HIV 免疫原性
  • 批准号:
    8131050
  • 财政年份:
    2009
  • 资助金额:
    $ 36.64万
  • 项目类别:
RNAi manipulations of DC to enhance HIV immunogenicity
DC 的 RNAi 操作增强 HIV 免疫原性
  • 批准号:
    7931973
  • 财政年份:
    2009
  • 资助金额:
    $ 36.64万
  • 项目类别:
RNAi manipulations of DC to enhance HIV immunogenicity
DC 的 RNAi 操作增强 HIV 免疫原性
  • 批准号:
    7761032
  • 财政年份:
    2009
  • 资助金额:
    $ 36.64万
  • 项目类别:
Targeted delivery of anti HIV sRNAs/shRNAs to T cells
将抗 HIV sRNA/shRNA 靶向递送至 T 细胞
  • 批准号:
    7339361
  • 财政年份:
    2007
  • 资助金额:
    $ 36.64万
  • 项目类别:
Targeted delivery of anti HIV sRNAs/shRNAs to T cells
将抗 HIV sRNA/shRNA 靶向递送至 T 细胞
  • 批准号:
    7683238
  • 财政年份:
    2007
  • 资助金额:
    $ 36.64万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 36.64万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 36.64万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 36.64万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 36.64万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 36.64万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 36.64万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 36.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 36.64万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 36.64万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 36.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了